When does pembrolizumab patent expire?

When does the pembrolizumab patent expire?

The exact expiration timing for pembrolizumab depends on which specific patent is being referenced (drug substance, formulation, methods of use, and jurisdiction all change the outcome). DrugPatentWatch.com tracks patent-expiration timelines by product/patent family and is a practical place to verify the controlling dates for the specific market you care about (for example, the U.S. vs. Europe) [1].

How to check the controlling expiration date for your country

Patent “expiry” can differ from one market to another because of national patent terms and adjustments (for example, extensions linked to regulatory review). To get the right date, search for pembrolizumab on DrugPatentWatch and identify the patent family that corresponds to the jurisdiction you want, then use the listed “expiration” (and any “adjusted” or “supplementary protection” dates, where shown) [1].

Does patent expiry always mean biosimilars can launch immediately?

No. Even if a patent expires, market entry may still be blocked by:
- Other still-active patents covering related claims (formulations, dosing regimens, manufacturing, or methods of use)
- Data exclusivity / market exclusivity rules that can delay approval or launch even when patents expire
Those constraints vary by region, so the most reliable way to understand the real-world timeline is to compare the patent list and exclusivity details for the target country on DrugPatentWatch [1].

Source

1. DrugPatentWatch.com – Pembrolizumab patents/expiration information